BioDuro understands the value our clients place on partnering with the right CRO/CDMO. We work as true partners throughout the discovery, development and manufacturing process, to provide a new and reliable source of efficiencies, ideas and innovation, while ensuring an exceptional customer experience.
BioDuro offers the first drug screening platform to combine humanized 3D tumor models in vitro and follow-on in vivo PDX capability, matched to same primary patient sample. Learn more about hTME-3DX Screen and Verify™ by downloading our fact sheet below.
Through the acquisition of Molecular Response, BioDuro’s oncology platform comprises the world’s largest viable tumor collection of over 100,000 biospecimens. Learn more about our capabilities by downloading the fact sheet below.
BioDuro Analytical Development provides necessary data for the development process from discovery candidates to clinical trial materials. Learn more about our capabilities by downloading our fact sheet below.
Effect of Nozzle Mechanism and Spray Dried Dispersion Parameters on Final Dissolution of Spray Dried Tablets
Scientific poster investigating the effect of change from a pressure nozzle to a two fluid nozzle on final quality attributes of a spray dried formulation of tablets and to determine the potential cause of quality attribute changes
Ex Vivo Three-dimensional Tumor Growth Assay: 3DX-TGA
Poster on the establishment, serial propagation and molecular characterization of 300+ ex vivo 3D (3DX) models spanning 16 tumor indications, as a practical alternative to PDX models. Presented by Brett Hall, Ph. D., at AACR 2017.
hTME-3DX Screen and Verify™ is based on the proprietary primary tumor bank and 3D drug screening platform that was developed by Molecular Response, through a large body of academic and commercial research over the past decade, as well as, internal expertise in ex vivo cell cultures and human tumor sample preservation.
Rapid Development and Scale-up of Solubilized Dosage Forms
Hear from Ruchit Trivedi Ph.D., Associate Director of Formulation at BioDuro on strategies for developing poorly soluble drugs. He discusses the advantages of amorphous materials and solubilization approaches using spray drying and hot melt extrusion.
Enabled Formulations Bridging Discovery and Development
Hear BioDuro’s CSO of Global CMC Solutions, Blair West, Ph.D., present on challenges and opportunities in late discovery and early development formulation and how a multidisciplinary approach that integrates areas such as formulation development and DMPK can accelerate the development pathway.
Paving the Road to the Clinic: Translational Oncology & Immuno-oncology Tumor Models
Hear from Tommy Broudy, Executive Vice President, Translational Sciences & Strategy on clinically relevant models for anti-cancer drug discovery. He discusses in vitro and in vivo models, the importance of the tumor microenvironment, and preclinical immunoprofiling of patient populations.